Yale Report Identified Risks in CMS Gene Therapy Model
Healthcare operators and state programs must navigate new outcome-based payment risks for million-dollar therapies.
Updated on Sept. 29, 2026 in Healthcare
Live Poll
Do you trust government programs to make expensive, life-saving gene therapies more affordable for patients?
Yale University researchers published an analysis of the Centers for Medicare & Medicaid Services Cell and Gene Therapy (CGT) Access Model. The report evaluates the initiative, which seeks to standardize multistate, outcome-based payment agreements for cell and gene therapies.
Why it matters
The model attempts to align payment with therapeutic benefits for therapies carrying multimillion-dollar price tags. However, the report highlights potential operational friction for state agencies and providers, including moral hazard risks and data collection complexities.
The study analyzed the CMS CGT Access Model, which manages therapies with multimillion-dollar upfront costs. Researchers identified critical data collection and moral hazard risks that remain unresolved in current federal frameworks.
The players
Centers for Medicare & Medicaid Services
The federal agency that administers the Medicaid program and sets national reimbursement policy for healthcare providers and manufacturers.
Yale University
An Ivy League research institution that conducts policy analysis on healthcare economics and public program administration.
The details
The CGT Access Model operates by having CMS negotiate core payment terms with drug manufacturers, which states then adopt through the Medicaid Drug Rebate Program. CMS acts as the central coordinator for data collection and contract administration across state lines. The Yale analysis warns that this structure complicates the tracking of patient outcomes when care is delivered out-of-state, potentially undermining the model's intent to base payments on actual therapeutic benefit.
Timeline
September 29, 2026: Researchers published the report on the CGT Access Model.
Market Landscape
This initiative attempts to modernize the Medicaid Drug Rebate Program to accommodate high-cost, one-time curative treatments. The model follows a broader industry trend of shifting away from traditional volume-based drug payments toward value-based, outcome-contingent models.
Providers and state-level healthcare operators should watch for secondary federal guidance on data collection requirements to assess potential administrative burdens. Compliance teams should specifically evaluate how current patient tracking systems align with proposed outcome-based reporting metrics.
The takeaway
Operators must balance the potential for high-cost drug access against the risk of unproven data collection mechanisms. Audit existing outcome-tracking capabilities to determine if your organization is prepared for standardized federal reporting requirements.
Further reading
For broader context on current industry shifts, see the latest updates in Healthcare.
More information
Read the full research findings in the journal article DOI.
Source note: This article includes information reported by InsuranceNewsNet.
Live Poll
Do you trust government programs to make expensive, life-saving gene therapies more affordable for patients?
